Physician profile
Samuel J Reck
NPI 1790832756
$332.14
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $20.50 · 2023: $138 · 2024: $174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $312.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $311.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $46.90 | 2023-2024 | Otezla |
| Novartis Pharmaceuticals Corporation | $46.60 | 2023-2024 | |
| Incyte Corporation | $38.46 | 2023-2024 | Opzelura |
| Abbvie INC. | $38.11 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $27.56 | 2024 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $26.48 | 2023-2024 | Sotyktu |
| Sanofi-Aventis U.S. LLC | $20.50 | 2020 | |
| Biofrontera INC. | $19.50 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Lilly USA, LLC | $19.36 | 2024 | Olumiant, Taltz |
| Genzyme Corporation | $18.89 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.90 | 2023 | Cyltezo |
| Janssen Biotech, INC. | $14.88 | 2023 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Reck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.